Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 5/20 | 0.60 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.55 |
| ▸ | CTSB | P07858 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | CASP6 | P55212 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.47 |
| ▸ | ABAT | P80404 | 1/20 | 0.47 |
| ▸ | ERN1 | O75460 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL4383863 | 0.98 | GPR35 (0.58) | GPR35HPGDSMN1; SMN2TP53TSHR | |
| Water SCHEMBL4383860 | 0.98 | GPR35 (0.58) | GPR35HPGDSMN1; SMN2TP53TSHR | |
| SCHEMBL3083253 | 0.90 | GPR35 (0.71) | GPR35HPGDSMN1; SMN2TP53TSHR | |
| SCHEMBL29533001 | 0.82 | GPR35 (0.59) | GPR35HPGDSMN1; SMN2TP53TSHR | |
| SCHEMBL70085 | 0.82 | GPR35 (0.59) | GPR35HPGDSMN1; SMN2TP53TSHR | |
| SCHEMBL68675 | 0.82 | GPR35 (0.59) | GPR35HPGDSMN1; SMN2TP53TSHR | |
| SCHEMBL12491862 | 0.80 | GPR35 (0.57) | GPR35HPGDSMN1; SMN2TP53TSHR | |
| SCHEMBL27718719 | 0.80 | HPGD (0.55) | GPR35HPGDSMN1; SMN2TP53TSHR | |
| SCHEMBL27469332 | 0.80 | GPR35 (0.57) | GPR35HPGDSMN1; SMN2TP53TSHR | |
| SCHEMBL3280548 | 0.80 | GPR35 (0.54) | GPR35HPGDSMN1; SMN2TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2437791-B1 | POTENTIATION OF AUTOIMMUNE AND INFLAMMATORY DISEASE TREATMENTS BY IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) ANTAGONISTS OF TLR7 AND TLR9 | IDERA PHARMACEUTICALS INC (US) | 2017-03-22 | — | — | EP | claimed |
| US-9206430-B2 | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response | IDERA PHARMACEUTICALS, INC. (US) | 2015-12-08 | — | — | US | claimed |
| EP-2343307-B1 | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response | IDERA PHARMACEUTICALS (US) | 2015-08-05 | — | — | EP | claimed |
| US-8987221-B2 | Potentiation of autoimmune and inflammatory disease treatments by immune regulatory oligonucleotide (IRO) antagonists of TLR7 and TLR9 | IDERA PHARMACEUTICALS, INC. (US) | 2015-03-24 | — | — | US | claimed |
| US-8853177-B2 | Use of inhibitors of toll-like receptors in the prevention and treatment of hypercholesterolemia and hyperlipidemia and diseases related thereto | IDERA PHARMACEUTICALS, INC. (US) | 2014-10-07 | — | — | US | claimed |
| US-20130267583-A1 | IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE | IDERA PHARMACEUTICALS, INC. (US) | 2013-10-10 | — | — | US | claimed |
| US-8426375-B2 | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response | IDERA PHARMACEUTICALS, INC. (US) | 2013-04-23 | — | — | US | claimed |
| US-8399423-B2 | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response | IDERA PHARMACEUTICALS, INC. (US) | 2013-03-19 | — | — | US | claimed |
| US-8383598-B2 | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response | IDERA PHARMACEUTICALS, INC. (US) | 2013-02-26 | — | — | US | claimed |
| US-8377898-B2 | Antisense oligonucleotides for prevention and/or treatment of infection, asthma, skin, inflammatory and/or autoimmune disorders | IDERA PHARMACEUTICALS, INC. (US) | 2013-02-19 | — | — | US | claimed |
| US-8357665-B2 | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response | IDERA PHARMACEUTICALS, INC. (US) | 2013-01-22 | — | — | US | claimed |
| EP-2451974-A2 | OLIGONUCLEOTIDE-BASED COMPOUNDS AS INHIBITORS OF TOLL-LIKE RECEPTORS | Idera Pharmaceuticals, Inc. (US) | 2012-05-16 | — | — | EP | claimed |
| EP-2343307-A1 | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response | Idera Pharmaceuticals (US) | 2011-07-13 | — | — | EP | claimed |
| WO-2011005942-A2 | OLIGONUCLEOTIDE-BASED COMPOUNDS AS INHIBITORS OF TOLL-LIKE RECEPTORS | IDERA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | claimed |
| US-20110009477-A1 | OLIGONUCLEOTIDE-BASED COMPOUNDS AS INHIBITORS OF TOLL-LIKE RECEPTORS | IDERA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | claimed |
| US-7539006-B2 | Electrolytic solution for driving electrolytic capacitor and electrolytic capacitor | RUBYCON CORPORATION (JP) | 2009-05-26 | — | — | US | claimed |
| US-20070029529-A1 | Electrolytic solution for driving electrolytic capacitor and electrolytic capacitor | KOMATSU AKIHIKO | 2007-02-08 | — | — | US | claimed |
| US-20040245105-A1 | Electrolyte solution for driving electrolytic capacitor and electrolytic capacitor | RUBYCON CORPORATION (JP) | 2004-12-09 | — | — | US | claimed |
| EP-1437749-A1 | ELECTROLYTE SOLUTION FOR DRIVING ELECTROLYTIC CAPACITOR AND ELECTROLYTIC CAPACITOR | Rubycon Corporation (JP) | 2004-07-14 | — | — | EP | claimed |
| EP-4029508-A1 | TREATMENT OF CANCER USING TLR9 AGONISTS AND CHECKPOINT INHIBITORS | Idera Pharmaceuticals, Inc. (US) | 2022-07-20 | — | — | EP | disclosed |
| EP-3204040-B1 | TREATMENT OF CANCER USING TLR9 AGONISTS AND CHECKPOINT INHIBITORS | IDERA PHARMACEUTICALS INC (US) | 2021-12-08 | — | — | EP | disclosed |
| EP-2348112-B1 | Stabilized immune modulatory RNA (SIMRA) compounds | IDERA PHARMACEUTICALS INC (US) | 2018-11-28 | — | — | EP | disclosed |
| US-20180044669-A1 | COMPOSITIONS FOR INHIBITING CHECKPOINT GENE EXPRESSION AND USES THEREOF | IDERA PHARMACEUTICALS, INC. | 2018-02-15 | — | — | US | disclosed |
| EP-3272870-A1 | COMPOSITIONS FOR INHIBITING GENE EXPRESSION AND USES THEREOF | Idera Pharmaceuticals, Inc. (US) | 2018-01-24 | — | — | EP | disclosed |
| US-9828601-B2 | Compositions for inhibiting checkpoint gene expression and uses thereof | IDERA PHARMACEUTICALS, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| EP-2960333-B1 | COMPOSITION FOR INHIBITING GENE EXPRESSION AND USES THEREOF | IDERA PHARMACEUTICALS INC (US) | 2017-10-04 | — | — | EP | disclosed |
| US-20170274004-A1 | TREATMENT OF CANCER USING TLR9 AGONIST WITH CHECKPOINT INHIBITORS | IDERA PHARMACEUTICALS INC (US) | 2017-09-28 | — | — | US | disclosed |
| US-20170145412-A1 | COMPOSITIONS FOR INHIBITING NLRP3 GENE EXPRESSION AND USES THEREOF | IDERA PHARMACEUTICALS, INC. | 2017-05-25 | — | — | US | disclosed |
| EP-2437791-B1 | POTENTIATION OF AUTOIMMUNE AND INFLAMMATORY DISEASE TREATMENTS BY IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) ANTAGONISTS OF TLR7 AND TLR9 | IDERA PHARMACEUTICALS INC (US) | 2017-03-22 | — | — | EP | disclosed |
| US-20170009230-A1 | COMPOSITIONS FOR INHIBITING DUX4 GENE EXPRESSION AND USES THEREOF | IDERA PHARMACEUTICALS, INC. | 2017-01-12 | — | — | US | disclosed |
| US-9453228-B2 | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response | IDERA PHARMACEUTICALS, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20160251652-A1 | COMPOSITIONS FOR INHIBITING CHECKPOINT GENE EXPRESSION AND USES THEREOF | NOVAQUEST CO-INVESTMENT FUND XV, L.P. | 2016-09-01 | — | — | US | disclosed |
| EP-2821488-B1 | Novel synthetic agonists of TLR9 | IDERA PHARMACEUTICALS INC (US) | 2016-07-27 | — | — | EP | disclosed |
| US-9347064-B2 | Methods of treatment using TLR7 and/or TLR9 inhibitors | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2016-05-24 | — | — | US | disclosed |
| US-20160138022-A1 | IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE | NOVAQUEST CO-INVESTMENT FUND XV, L.P. | 2016-05-19 | — | — | US | disclosed |
| US-20160101128-A1 | TREATMENT OF CANCER USING TLR9 AGONIST WITH CHECKPOINT INHIBITORS | IDERA PHARMACEUTICALS, INC. | 2016-04-14 | — | — | US | disclosed |
| US-9243050-B2 | Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8 | Idera Pharamaceuticals, Inc. (US) | 2016-01-26 | — | — | US | disclosed |
| EP-2960333-A1 | COMPOSITION FOR INHIBITING GENE EXPRESSION AND USES THEREOF | Idera Pharmaceuticals, Inc. (US) | 2015-12-30 | — | — | EP | disclosed |
| EP-2343307-B1 | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response | IDERA PHARMACEUTICALS (US) | 2015-08-05 | — | — | EP | disclosed |
| US-20150203850-A1 | METHODS OF TREATMENT USING TLR7 AND/OR TLR9 INHIBITORS | DYNAVAX TECHNOLOGIES CORPORATION | 2015-07-23 | — | — | US | disclosed |
| EP-1934239-B1 | IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE | IDERA PHARMACEUTICALS INC (US) | 2015-07-15 | — | — | EP | disclosed |
| US-8987221-B2 | Potentiation of autoimmune and inflammatory disease treatments by immune regulatory oligonucleotide (IRO) antagonists of TLR7 and TLR9 | IDERA PHARMACEUTICALS, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8940310-B2 | Methods of treatment using TLR7 and/or TLR9 inhibitors | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2015-01-27 | — | — | US | disclosed |
| US-8877722-B2 | Compositions for inhibiting gene expression and uses thereof | IDERA PHARMACEUTICALS, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20140308300-A1 | STABILIZED IMMUNE MODULATORY RNA (SIMRA) COMPOUNDS FOR TLR7 AND TLR8 | NOVAQUEST CO-INVESTMENT FUND XV, L.P. | 2014-10-16 | — | — | US | disclosed |
| EP-2726529-A1 | HYBRID EPOXY RESINS | Dow Global Technologies LLC (US) | 2014-05-07 | — | — | EP | disclosed |
| US-20130142778-A1 | COMPOSITIONS FOR INHIBITING GENE EXPRESSION AND USES THEREOF | IDERA PHARMACEUTICALS, INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-8426375-B2 | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response | IDERA PHARMACEUTICALS, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| WO-2013055411-A1 | HYBRID EPOXY RESINS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2013-04-18 | — | — | WO | disclosed |
| US-8399423-B2 | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response | IDERA PHARMACEUTICALS, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8362233-B2 | Stabilized immune modulatory RNA (SIMRA) compounds | IDERA PHARMACEUTICALS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8357665-B2 | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response | IDERA PHARMACEUTICALS, INC. (US) | 2013-01-22 | — | — | US | disclosed |
| US-20120183530-A1 | STABILIZED IMMUNE MODULATORY RNA (SIMRA) COMPOUNDS | IDERA PHARMACEUTICALS, INC. | 2012-07-19 | — | — | US | disclosed |
| US-8188261-B2 | Stabilized immune modulatory RNA (SIMRA) compounds | IDERA PHARMACEUTICALS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-8106173-B2 | Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8 | IDERA PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20120016004-A1 | COMPOSITIONS FOR INHIBITING GENE EXPRESSION AND USES THEREOF | IDERA PHARMACEUTICALS, INC. | 2012-01-19 | — | — | US | disclosed |
| EP-2357231-A2 | Stabilized immune modulatory RNA (SIMRA) compounds | Idera Pharmaceuticals, Inc. (US) | 2011-08-17 | — | — | EP | disclosed |
| EP-2348112-A2 | Stabilized immune modulatory RNA (SIMRA) compounds | Idera Pharmaceuticals, Inc. (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20110171209-A1 | Potentiation of Autoimmune and Inflammatory Disease Treatments by Immune Regulatory Oligonucleotide (IRO) Antagonists of TLR7 and TLR9 | IDERA PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| US-7960362-B2 | Synthetic agonists of TLR9 | IDERA PHARMACEUTICALS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20110009477-A1 | OLIGONUCLEOTIDE-BASED COMPOUNDS AS INHIBITORS OF TOLL-LIKE RECEPTORS | IDERA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-7833331-B2 | Non-toxic corrosion-protection pigments based on cobalt | UNIVERSITY OF DAYTON (US) | 2010-11-16 | — | — | US | disclosed |
| US-7789958-B2 | Non-toxic corrosion-protection pigments based on manganese | UNIVERSITY OF DAYTON (US) | 2010-09-07 | — | — | US | disclosed |
| US-20090163628-A1 | NON-TOXIC CORROSION-PROTECTION PIGMENTS BASED ON COBALT | STURGILL JEFFREY ALLEN | 2009-06-25 | — | — | US | disclosed |
| US-7539006-B2 | Electrolytic solution for driving electrolytic capacitor and electrolytic capacitor | RUBYCON CORPORATION (JP) | 2009-05-26 | — | — | US | disclosed |
| US-20090098063-A1 | IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE | IDERA PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090087388-A1 | IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE | IDERA PHARMACEUTICALS, INC. | 2009-04-02 | — | — | US | disclosed |
| US-20090060898-A1 | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response | IDERA PHARMACEUTICALS, INC. | 2009-03-05 | — | — | US | disclosed |
| US-20090053206-A1 | NOVEL SYNTHETIC AGONISTS OF TLR9 | IDERA PHARMACEUTICALS, INC. | 2009-02-26 | — | — | US | disclosed |
| US-20090053205-A1 | STABILIZED IMMUNE MODULATORY RNA (SIMRA) COMPOUNDS | IDERA PHARMACEUTICALS, INC | 2009-02-26 | — | — | US | disclosed |
| US-7422793-B2 | Non-toxic corrosion-protection rinses and seals based on rare earth elements | UNIVERSITY OF DAYTON (US) | 2008-09-09 | — | — | US | disclosed |
| US-7407711-B2 | Non-toxic corrosion-protection conversion coats based on rare earth elements | UNIVERSITY OF DAYTON (US) | 2008-08-05 | — | — | US | disclosed |
| US-20080171712-A1 | At least two oligonucleotides having modified purine bases, such as deazaguanosines or deaza-adenosines, linked by an alkyl or phenolic diol or triol; vaccines, DNA vaccines; anticarcinogenic, antiallergenic, antiinflammatory agents; bronchodilators | IDERA PHARMACEUTICALS, INC. | 2008-07-17 | — | — | US | disclosed |
| US-7294211-B2 | Non-toxic corrosion-protection conversion coats based on cobalt | UNIVERSITY OF DAYTON (US) | 2007-11-13 | — | — | US | disclosed |
| US-7291217-B2 | Non-toxic corrosion-protection pigments based on rare earth elements | UNIVERSITY OF DAYTON (US) | 2007-11-06 | — | — | US | disclosed |
| US-20070149673-A1 | NON-TOXIC CORROSION-PROTECTION PIGMENTS BASED ON MANGANESE | STURGILL JEFFREY A | 2007-06-28 | — | — | US | disclosed |
| US-7235142-B2 | Non-toxic corrosion-protection rinses and seals based on cobalt | UNIVERSITY OF DAYTON (US) | 2007-06-26 | — | — | US | disclosed |
| CN-1316061-C | Composition and treatment liquid for surface treatment, surface treatment method and product with metal material | NIPPON BACAREI KAMIYA CORP (JP) | 2007-05-16 | — | — | CN | disclosed |
| US-20070029529-A1 | Electrolytic solution for driving electrolytic capacitor and electrolytic capacitor | KOMATSU AKIHIKO | 2007-02-08 | — | — | US | disclosed |
| US-20040245105-A1 | Electrolyte solution for driving electrolytic capacitor and electrolytic capacitor | RUBYCON CORPORATION (JP) | 2004-12-09 | — | — | US | disclosed |
| EP-1472319-A1 | NON-TOXIC CORROSION PROTECTION PIGMENTS BASED ON COBALT | UNIVERSITY OF DAYTON (US) | 2004-11-03 | — | — | EP | disclosed |
| WO-2004065305-A1 | NON-TOXIC CORROSION-PROTECTION PIGMENTS BASED ON MANGANESE | UNIVERSITY OF DAYTON (US) | 2004-08-05 | — | — | WO | disclosed |
| EP-1437749-A1 | ELECTROLYTE SOLUTION FOR DRIVING ELECTROLYTIC CAPACITOR AND ELECTROLYTIC CAPACITOR | Rubycon Corporation (JP) | 2004-07-14 | — | — | EP | disclosed |
| US-20040104377-A1 | Non-toxic corrosion-protection pigments based on rare earth elements | UNIVERSITY OF DAYTON | 2004-06-03 | — | — | US | disclosed |
| CN-1493712-A | Composition and treatment liquid for surface treatment, surface treatment method and product with metal material | 日本巴卡黎神谷股份有限公司 | 2004-05-05 | — | — | CN | disclosed |
| US-20040020568-A1 | Non-toxic corrosion-protection conversion coats based on rare earth elements | DAYTON, UNIVERSITY OF | 2004-02-05 | — | — | US | disclosed |
| US-20040016910-A1 | Non-toxic corrosion-protection rinses and seals based on rare earth elements | DAYTON, UNIVERSITY OF | 2004-01-29 | — | — | US | disclosed |
| US-20040011252-A1 | Non-toxic corrosion-protection pigments based on manganese | UNIVERSITY OF DAYTON | 2004-01-22 | — | — | US | disclosed |
| US-20030234063-A1 | Non-toxic corrosion-protection conversion coats based on cobalt | DAYTON, UNIVERSITY OF | 2003-12-25 | — | — | US | disclosed |
| US-20030230363-A1 | Non-toxic corrosion-protection rinses and seals based on cobalt | UNIVERSITY OF DAYTON | 2003-12-18 | — | — | US | disclosed |
| WO-2003060192-A1 | NON-TOXIC CORROSION-PROTECTION RINSES AND SEALS BASED ON COBALT | UNIVERSITY OF DAYTON (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003060191-A2 | NON-TOXIC CORROSION-PROTECTION CONVERSION COATINGES ABSED ON COBALT | UNIVERSITY OF DAYTON (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003060019-A1 | NON-TOXIC CORROSION PROTECTION PIGMENTS BASED ON COBALT | UNIVERSITY OF DAYTON (US) | 2003-07-24 | — | — | WO | disclosed |
| EP-0509451-B1 | Improved solid electrolytic capacitors and method for manufacturing the same | MATSUSHITA ELECTRIC INDUSTRIAL CO LTD (JP) | 1995-03-29 | — | — | EP | disclosed |
| US-5276174-A | Alk-1-enyloxy carbonates | ISP INVESTMENTS INC. (US) | 1994-01-04 | — | — | US | disclosed |
| EP-0514482-A4 | VINYL ETHER COMPOUNDS | — | 1993-04-21 | — | — | EP | disclosed |
| US-5187650-A | Having valve metal with oxide layer, conductive polymer and support electrolyte with nitro group | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 1993-02-16 | — | — | US | disclosed |
| EP-0514482-A1 | VINYL ETHER COMPOUNDS | ISP INVESTMENTS INC. (US) | 1992-11-25 | — | — | EP | disclosed |
| EP-0509451-A1 | Improved solid electrolytic capacitors and method for manufacturing the same | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 1992-10-21 | — | — | EP | disclosed |
| US-5087548-A | POSITIVE TYPE RADIATION-SENSITIVE RESIN COMPOSITION | JAPAN SYNTHETIC RUBBER CO., INC. (JP) | 1992-02-11 | — | — | US | disclosed |
| WO-1991013052-A1 | VINYL ETHER COMPOUNDS | ISP INVESTMENTS INC. (US) | 1991-09-05 | — | — | WO | disclosed |
| EP-0227487-A2 | Positive type radiation-sensitive resin composition | JAPAN SYNTHETIC RUBBER CO., LTD. (JP) | 1987-07-01 | — | — | EP | disclosed |
| EP-0153642-A2 | Process for the preparation of monomeric aromatic hydroxyurethanes | BAYER AG (DE) | 1985-09-04 | — | — | EP | disclosed |
| US-4491584-A | ANTIARRHYTHMIA AGENTS | RIKER LABORATORIES (US) | 1985-01-01 | — | — | US | disclosed |
| EP-0095454-A2 | Nuclens-substituted pyrogallol derivatives | Gerot-Pharmazeutika Gesellschaft m.b.H. (AT) | 1983-11-30 | — | — | EP | disclosed |
| US-4355141-A | NITROGEN-COMPOUND CONTAINING RESOLE RESIN PREVENTS STICKING | MITSUI TOATSU CHEMICAL, INC. (JP) | 1982-10-19 | — | — | US | disclosed |
| US-4154941-A | ANTIARRHYTHMIC AGENTS | RIKER LABORATORIES, INC. (US) | 1979-05-15 | — | — | US | disclosed |
| US-4071524-A | Derivatives of urea | RIKER LABORATORIES, INC. (US) | 1978-01-31 | — | — | US | disclosed |
| US-4071524-A | Derivatives of urea | RIKER LABORATORIES, INC. (US) | 1978-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (19 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090053206-A1 | NOVEL SYNTHETIC AGONISTS OF TLR9 | TLR9, TLR3, TLR7 | GPR35 108/4885HPGD 3125/4885SMN1; SMN2 4242/4885 |
| US-20170145412-A1 | COMPOSITIONS FOR INHIBITING NLRP3 GENE EXPRESSION AND USES THEREOF | NLRP3, RNMT, NOD1 | GPR35 1822/4885HPGD 3411/4885SMN1; SMN2 3008/4885 |
| US-20160101128-A1 | TREATMENT OF CANCER USING TLR9 AGONIST WITH CHECKPOINT INHIBITORS | TLR9, TLR3, TLR7 | GPR35 211/4885HPGD 4283/4885SMN1; SMN2 2898/4885 |
| US-20110009477-A1 | OLIGONUCLEOTIDE-BASED COMPOUNDS AS INHIBITORS OF TOLL-LIKE RECEPTORS | TLR3, TLR9, TLR1 | GPR35 213/4885HPGD 4498/4885SMN1; SMN2 3841/4885 |
| US-20160138022-A1 | IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE | TLR3, TLR9, TLR5 | GPR35 87/4885HPGD 4418/4885SMN1; SMN2 4083/4885 |
| US-20180044669-A1 | COMPOSITIONS FOR INHIBITING CHECKPOINT GENE EXPRESSION AND USES THEREOF | CD274, PDCD1LG2, PDCD1 | GPR35 1624/4885HPGD 4222/4885SMN1; SMN2 1735/4885 |
| US-20120016004-A1 | COMPOSITIONS FOR INHIBITING GENE EXPRESSION AND USES THEREOF | RNGTT, NSUN2, RTCB | GPR35 4267/4885HPGD 4586/4885SMN1; SMN2 951/4885 |
| US-20170009230-A1 | COMPOSITIONS FOR INHIBITING DUX4 GENE EXPRESSION AND USES THEREOF | DDX21, DDX24, DDX3X | GPR35 4327/4885HPGD 3578/4885SMN1; SMN2 1177/4885 |
| US-20160251652-A1 | COMPOSITIONS FOR INHIBITING CHECKPOINT GENE EXPRESSION AND USES THEREOF | CD274, PDCD1LG2, PDCD1 | GPR35 1624/4885HPGD 4222/4885SMN1; SMN2 1735/4885 |
| US-20110171209-A1 | Potentiation of Autoimmune and Inflammatory Disease Treatments by Immune Regulatory Oligonucleotide (IRO) Antagonists of TLR7 and TLR9 | TLR9, TLR7, TLR3 | GPR35 284/4885HPGD 4489/4885SMN1; SMN2 2459/4885 |
| US-20090087388-A1 | IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE | TLR3, TLR9, TLR5 | GPR35 87/4885HPGD 4418/4885SMN1; SMN2 4083/4885 |
| US-20130142778-A1 | COMPOSITIONS FOR INHIBITING GENE EXPRESSION AND USES THEREOF | AGO2, NSUN2, ZFR | GPR35 4740/4885HPGD 4731/4885SMN1; SMN2 1291/4885 |
| US-20090060898-A1 | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response | TLR3, TLR9, TLR5 | GPR35 87/4885HPGD 4418/4885SMN1; SMN2 4083/4885 |
| US-20080171712-A1 | At least two oligonucleotides having modified purine bases, such as deazaguanosines or deaza-adenosines, linked by an alkyl or phenolic diol or triol; vaccines, DNA vaccines; anticarcinogenic, antiallergenic, antiinflammatory agents; bronchodilators | TLR8, TLR7, TLR9 | GPR35 167/4885HPGD 3729/4885SMN1; SMN2 2543/4885 |
| US-20090098063-A1 | IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE | TLR3, TLR9, TLR1 | GPR35 338/4885HPGD 4517/4885SMN1; SMN2 3163/4885 |
| US-20170274004-A1 | TREATMENT OF CANCER USING TLR9 AGONIST WITH CHECKPOINT INHIBITORS | TLR9, TLR3, TLR7 | GPR35 211/4885HPGD 4283/4885SMN1; SMN2 2898/4885 |
| US-20120183530-A1 | STABILIZED IMMUNE MODULATORY RNA (SIMRA) COMPOUNDS | TLR8, TLR7, TLR9 | GPR35 2380/4885HPGD 4838/4885SMN1; SMN2 311/4885 |
| US-20140308300-A1 | STABILIZED IMMUNE MODULATORY RNA (SIMRA) COMPOUNDS FOR TLR7 AND TLR8 | TLR8, TLR7, TLR9 | GPR35 1993/4885HPGD 4809/4885SMN1; SMN2 400/4885 |
| US-20090053205-A1 | STABILIZED IMMUNE MODULATORY RNA (SIMRA) COMPOUNDS | TLR8, TLR7, TLR9 | GPR35 2380/4885HPGD 4838/4885SMN1; SMN2 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.